Reuters logo
BRIEF-Trius Therapeutics up in premarket after tedizolid study results
March 25, 2013 / 12:10 PM / 5 years ago

BRIEF-Trius Therapeutics up in premarket after tedizolid study results

NEW YORK, March 25 (Reuters) - Trius Therapeutics Inc : * Up 6.6 percent to $7.45 in premarket after tedizolid study results

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below